Pancreatic Cancer
One of the deadliest major cancers, often diagnosed late; most cases are driven by KRAS mutations.
Coverage of Pancreatic Cancer is holding steady : 7 signals on the latest tracked day, up 75% from its three-week baseline of 4, across 4 domains (down from 6 a week ago). That makes it the #163 most-covered of the 348 concerns we track.
What’s changed
- The Times They Are A-Changin': Pancreatic Cancer Surgery in the RAS Inhibitor Era. · Ann Surg Oncol · 2026-09-01
- Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis. · J Food Sci · 2026-09-01
- RASolute 302: Lessons Learned and the Road Ahead in Pancreatic Cancer. · Oncologist · 2026-08-28
- EREG Emerges as a Potential Key Player in Pancreatic Cancer · Inside Precision Medicine · 2026-09-03 · usually covers Precision Medicine
- Business Watch: Solstice, Element cancel deal; FDA approves daraxonrasib for pancreatic cancer · Chemical & Engineering News · 2026-09-02 · usually covers Chemicals
- Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer - OncLive · KRAS Mutation Research (Google News) · 2026-09-01 · usually covers Kras Research
What the reporting says
Across 106 tracked stories from 45 outlets, reporting on Pancreatic Cancer most often describes regulatory approvals (27), acquisition (2), launches or releases (2), military action (1), award (1), meetings or visits (1).
It shows up alongside KRAS (49), Pdac (18), G12d (14), Lung Cancer (11), FDA (36), Colorectal Cancer (10), Immunotherapy (9).
Two steps out: KRAS Mutant (through KRAS, 46 shared stories on the weaker link); AI (through FDA, 36 shared stories on the weaker link); Cder (through FDA, 36 shared stories on the weaker link); Drug Administration (through FDA, 36 shared stories on the weaker link).
Tracked since Mar 12, with coverage on 52 separate days — concentrated in Oncology and Pubmed Targeted.